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Abstract
Chronic low back pain (CLBP) is one of the most common medical conditions, ranking as
the greatest contributor to global disability and accounting for huge societal costs based on
the Global Burden of Disease 2010 study.
Large genetic and -omics studies provide a promising avenue for the screening, develop-
ment and validation of biomarkers useful for personalized diagnosis and treatment (preci-
sion medicine). Multicentre studies are needed for such an effort, and a standardized and
homogeneous approach is vital for recruitment of large numbers of participants among dif-
ferent centres (clinical and laboratories) to obtain robust and reproducible results. To date,
no validated standard operating procedures (SOPs) for genetic/-omics studies in chronic
pain have been developed.
In this study, we validated an SOP model that will be used in the multicentre (5 centres)
retrospective “PainOmics” study, funded by the European Community in the 7th Framework
Programme, which aims to develop new biomarkers for CLBP through three different -omics
approaches: genomics, glycomics and activomics.
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The SOPs describe the specific procedures for (1) blood collection, (2) sample process-
ing and storage, (3) shipping details and (4) cross-check testing and validation before
assays that all the centres involved in the study have to follow.
Multivariate analysis revealed the absolute specificity and homogeneity of the samples
collected by the five centres for all genetics, glycomics and activomics analyses.
The SOPs used in our multicenter study have been validated. Hence, they could repre-
sent an innovative tool for the correct management and collection of reliable samples in
other large-omics-based multicenter studies.
Introduction
Chronic low back pain (CLBP) is broadly defined as pain, muscle tension, or stiffness localized
below the costal margin and above the inferior gluteal folds, with or without sciatica, which
persists for 12 weeks or more [1]. The prevalence of chronic low back pain (CLBP) has been
rising with a variable prevalence in the USA up to 10.2% [2] and in Brazil up to 9.6% [3]. It
accounts for considerable direct and indirect burdens for society, industry and healthcare sys-
tems [4, 5] representing the fifth most common reason for medical treatment, costing up to 50
billion dollars in the United States annually [6].
Low back pain (LBP) encompasses a group of mixed pain syndromes with poor correlation
between clinical manifestations and variable underlying mechanisms, anatomical lesions, neu-
ral pathways (neuropathic and nociceptive) and molecular pathologies. The high inter-individ-
ual variability in pain sensation and analgesic with similar “macroscopic” pathology (e.g. disc
herniation, arthrosis) is not well understood [7]. Various psychosocial characteristics influence
symptoms and prognosis in LBP and these include demographic factors (educational status,
age, gender), occupational factors (employment), mental health morbidity (anxiety, depres-
sion), perception of pain and disability (pain intensity and expectation of persistent pain) and
other psychological factors (fear avoidance, catastrophising, illness perceptions) [8].
To add to the heterogeneity of low back pain syndromes, given there is an underlying
inflammatory process involved in the experience of pain, our work in other diseases with
inflammatory components [9] suggests that biomarkers have a potential role to play in predict-
ing the risk of disease development and prognosis. The majority of studies that have investi-
gated genetic biomarkers have focused their attention predominantly on disk degeneration
and not so much on the low back pain syndrome [10, 11].
Under the 7th Framework Programme The European Community has funded a project
called “Multi-dimensional -omics approach to stratification of patients with low back pain”
(Acronym: PainOmics). As part of this study we will perform a retrospective study to compare
the “omics biomarkers” in approximately 4000 patients with CLBP to those of about 8000 con-
trol individuals without CLBP with three different types of -omics: genomics, glycomics (anal-
ysis of specific changes in glycan structures) and activomics (analysis of enzymatic activity of
numerous post-translational modification proteins).
Our aim is to find biomarkers associated with chronic pain and with the response to spe-
cific treatments, in order to obtain the safest and the most effective management of CLBP for
each patient.
As these studies require large sample sizes in order to find statistically significant results,
enrolment is usually done in various clinical centres. Moreover, the analysis of biological mate-
rial is also usually done in geographically separated laboratories. Consequently, harmonisation
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of the procedures used in collecting, handling (e.g. length of time to processing, storage, centri-
fugation, etc.), shipping and, finally, analysing the samples is of prime importance in order to
keep variance to a minimum. Unfortunately, until now there are no standard operating proce-
dures (SOP) for sample collection, validated for use in multicentre chronic pain studies.
Hence, SOPs were developed to provide details for conducting the study, phase by phase,
with written instructions to achieve uniformity of the procedures used for obtaining patient
blood for -omics analysis techniques, storing the samples, and shipping the aliquots to the spe-
cialized laboratories.
In this study we present the results of the validation of these SOPs, by showing their efficacy
in all the three specialized laboratories for the “omics” analysis included in the “PainOmics”
Consortium. We used the samples collected from the first 10 patients enrolled in each of the 5
Clinical Centres to validate the specific procedures hat least in triplicate test. In fact, the varia-
tions in blood collection between several Centres is a common problem leading to misleading
results in many–omics studies. The reproducibility of the SOPs cannot be assumed but
requires empirical testing, and this is the very point of this pilot study.
Materials and methods
We validated SOPs used in the PainOmics retrospective study to find -omics biomarker to
stratify patients with chronic low back pain recruited in the second middle of 2014. The Insti-
tution that granted permission is the Ethics Committee of each Center where patients were
enrolled after signed informed consentand it was registered on http://clinicaltrials.gov
(NCT02037789).
In particular, this study is approved by Ethic Committee of:
• University of Parma (UNIPR)—Italy;
• Fondazione IRCCS Policlinico San Matteo Hospital (OSM)—Italy;
• St. Catherine Specialty (St-Cat)—Croatia;
• Ziekenhuis Oost-Limburg Autonomeh Verzorgingsinstelling (ZOL)—Belgium;
• The Center for Clinical Research (CPI)—USA;
• Edith Cowan University (ECU)—Australia.
and the results of this study were already published in our manuscript on BMJ Open [12].
The SOPs were validated on 10 patients enrolled by each of the clinical centres for the Pai-
nOmics retrospective study. In the Table 1 we list the centres participating in the study and
highlight their role. The SOPs were discussed before the beginning of the trial and then finally
adopted and presented to the Ethics Committee of each clinical centre. We developed three
SOPs; DNA SOP, Plasma SOP, and Serum SOP for genomics, glycomics and activomics analy-
ses, respectively. All the clinical centres had to guarantee that the biological samples from each
patient are prepared, stored, and shipped following the analytical procedures defined in the
each of three SOPs.
All the patients undergo blood sampling for -omics determinations. The samples are then
divided into two vacutainers containing EDTA for genetic and glycomic analyses and into one
serum vacutainer with clot activator plus gel for activomics analyses.
Each sample is coded as follow:
PO—RT—acronym of participating centre—progressive number of enrolment–GEN/GLY/
ACT respectively for genomics, glycomics and activomics analyses.
“PO” indicates the acronym of Pain OMICS; “RT” indicates the retrospective study.
Validation of SOPs
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Each centre will keep the list of codes assigned to its patients, at least until the end of the
study.
Within the SOPs a specific time line was fixed, in order to standardize the maximum time
frame used for every single step during the process. A detailed method description with
defined guidelines was created for the following steps: collection of patient blood sample by
using printed labels on each cryotube; transfer of samples to the laboratory; processing, ali-
quoting and freezing of each sample; also shipping conditions were described including time
and storage requests.
The amount of DNA and concentration, as well as numbers of required aliquots required
for glycomics and activomics were defined and deviations from SOPs are allowed only if prop-
erly justified and shared with the laboratory supervisor (S1–S3 Files).
Finally, a procedure was set up to manage clinical samples whereby all samples are validated
for sample integrity (i.e. frozen, bar coded) and entered into a database for subsequent analy-
ses. The database identifies the storage location, temperature, number of freeze-thaw cycles,
remaining volume, and details on multiple aliquoting analyses. The primary database is linked
via barcode references to a second database that identifies screening results for the multiple
markers to be tested. The database also collates sample data from the same patient in order to
manage data collected sequentially over the study. The data will be centralized in a specific
web-based database (REDCap1).
Validation of the SOPs
A cross-check between the central laboratory and each laboratory of the clinical centres is a
key step before performing the analyses. Therefore, the three specialized -omics laboratories
described above, received samples from the first 10 patients enrolled by each of the five clinical
centres in order to validate the procedures.
DNA SOP. The quality and concentration of DNA samples extracted from blood need to
be validated to check if they were sufficient for downstream analysis. We identified a number
of key technical aspects that contribute to inter-assay variability. These include simple steps
such as using different DNA extraction kits (e.g., magnetic beads, columns, etc.).
DNA was extracted from whole blood and subsequently stored at -20˚C or -80˚C. DNA
samples were shipped on dry ice to the central laboratory. Of the first ten enrolled patients
from each clinical centre, 2 μg of DNA with a concentration of at least 50 ng/μL was used for
Table 1. Participating centres of the PainOmics study.
Name of the Centre Activity Sample Code
University of Parma (UNIPR)–Italy Enrolment of patients UPRRT
Fondazione IRCCS Policlinico San Matteo Hospital (OSM)—Italy Enrolment of patients OSMRT
St. Catherine Specialty Hospital (St-Cat)—Croatia Enrolment of patients STCAT
ZiekenhuisOost-Limburg Autonome
Verzorgingsinstelling (ZOL)—Belgium
Enrolment of patients ZOLRT
The Center for Clinical Research (CPI)—USA Enrolment of patients CPIRT
Genos DOO Za Vjestacenje i analizu (GENOS DOO)—Croatia Glycomics analysis
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum FuerGesundheit Und UmweltGmbh
(HMGU)—Germany
Genomics analysis
IP Research Consulting SASU(PHOTEOMIX)—France Activomics analysis
Edith Cowan University (ECU)—Australia Enrolment of patients
King’s College London (KCL)—UK Enrolment of patients
PolyOmica—The Netherlands Statistical analysis
https://doi.org/10.1371/journal.pone.0176372.t001
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validation (S1 File). DNA degradation, DNA integrity as well as sex determination of DNA
samples were analysed in all test samples. The DNA quality was assessed by gel electrophoresis
and spectrophotometric quantification. The DNA quality was defined according to the ratio of
absorbance (nm) at 260/280 (not less than 1.8) and at 260/230 (between 1.8 and 2.2). For sex
determination of DNA samples an amelogenin polymerase chain reaction (PCR) was per-
formed. The length of the gene amelogenin is different depending on the X or Y chromosome
and thus can be used to distinguish male and female samples. Moreover, this method evaluates
if the DNA is suitable for further processing.
High quality DNA samples are required to generate genome-wide genotype data using
high-throughput Illumina and Affymetrix genotyping platforms.
Plasma SOP. The blood dedicated to glycomics analysis was mixed well in the collection
tube for balanced clotting. It was left at room temperature before centrifugation, which should
be performed within 1 h. After separation of the plasma, the specimen was promptly divided
into aliquots of 1 mL using well-sealed freezing containers and immediately stored at -80˚C or
-20˚C. All aliquots that have not been taken for local use were shipped on dry ice to the central
laboratory for collective measurement. The aliquots must be kept at each laboratory to use for
cross-check testing to be done at the time of the assays by the central laboratory (S2 File). To
enable this highly sophisticated and novel analysis of glycomics at Genos ltd. in Croatia, a cus-
tom-built instrument that will combine nano-LC from Waters and an ESI-TOF detector from
Bruker was procured and installed. Upon initial installation a full test of the validation proce-
dure was completed. In particular, glycomics analyses were performed immunoglobulin G
(IgG) isolated from plasma samples by affinity chromatography using 96-well monolithic
plates with Protein G as previously described [13]. N-glycans were released from total proteins
and IgG by overnight deglycosylation with N-glycosidase F (PNG-ase F). Released N-glycans
were fluorescently labelled with a 2-aminobenzamide (2-AB) fluorescent tag and purified by
hydrophilic interaction liquid chromatography (HILIC) solid phase extraction (SPE). The
labelled N-glycans were analysed by hydrophilic interaction chromatography on a Waters
Acquity UPLC instrument using a Waters BEH Glycan chromatography column, 100 mM
ammonium formate, pH 4.4, as solvent A and acetonitrile as solvent B. The system was cali-
brated using an external standard of hydrolyzed and 2-AB labelled glucose oligomers from
which the retention times for the individual glycans were converted to glucose units. The data
extraction was performed with an automatic processing method after which each chromato-
gram was manually corrected to maintain the same intervals of integration for all the samples.
Finally, the chromatograms were separated into peaks in the same manner and the amount of
glycans in each peak was expressed as percentage of the total integrated area.
Serum SOP. The blood collected for activomics analysis was mixed well within the collec-
tion tube and left to clot for at least 1 h at 4˚C before centrifugation. After separation of the
serum, the specimen was divided into aliquots of 500 μL using well-sealed freezing containers
and immediately stored at -80˚C or -20˚C. For this highly sophisticated and novel analysis of
enzyme activity, 2 aliquots were sent to Photeomix (S3 File). Two activomics markers were
chosen to validate the sample stability before subsequent analysis for biomarkers was per-
formed. Marker Act011has been characterized as a robust indicator of sample integrity
because it measures serum proteolytic activity which is sensitive to storage conditions and
potential sample mishandling. Previous cross-reference between approx. 2000 serum samples
from different patients and from different centres has shown that this marker is invariant by
Receiver Operator Characteristic (ROC) analysis (ROC Area Under the Curve (AUC) value
0.5 ± 0.05)except where samples have been mishandled (e.g. when left at temperatures > 22˚C
for several hours/days). Marker Act02 has been characterised as a sensitive indicator of differ-
ent sample preparation techniques, particularly where uncontrolled lysis of blood cells can
Validation of SOPs
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‘contaminate’ sera with confounding cell-derived activities. Samples collected and validated,
will be handled and analysed in a way that minimises freeze-thaw cycles. For each enzymatic
reaction tested, 1–5 μL of serum from patients and healthy controls will be incubated with the
appropriate activomics1 substrate under controlled conditions (time, temperature, optimised
buffer conditions, etc.). Enzymatic modifications of the substrate will be monitored quantita-
tively by proprietary charge-based microfluidic assays for subsequent statistical analysis. The
assays will be repeated for a panel of different substrates in order to provide a wide view of dis-




First results of quality control showed sub-par DNA quality in almost all investigated test
samples. DNA samples from 4 clinical centres revealed concentrations below 50 ng/μL,
Fig 1. DNA concentration before and after validation. DNA concentrations (mean ± SD) of DNA test samples in duplicate. Dots indicate single DNA
samples of Clinical Centres before and after SOP adjustment.
https://doi.org/10.1371/journal.pone.0176372.g001
Validation of SOPs
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mainly caused by having less starting volume of blood and differences in calibration of mea-
suring instruments between the participating centres and the central laboratory. After
increasing the amount of blood and adjusting the SOP accordingly, DNA concentrations
were sufficient and reached expected values above 50 ng/μL (Fig 1). With this updated of the
SOP all DNA samples successfully passed quality control and showed satisfying results con-
cerning DNA quality and quantity. Moreover, amelogenin PCR has exactly identified the
gender of samples, compared to the study databases. This process was necessary to validate
the established SOP and to ensure high quality DNA samples which can then be used for fur-
ther downstream analysis (e.g. GWA studies) and also to exclude any mix up of already
encoded samples.
Glycomics and plasma check
Plasma check was performed for all 10 obtained samples. From each plasma sample 10 μL was
taken and denatured with SDS and temperature. N-glycans were released with PNG-ase F and
the released N-glycans were labelled with 2-AB. UPLC analysis was performed as mentioned
above and the obtained chromatograms were separated into 39 glycan peaks (GP) (Fig 2). All
samples passed our quality control (peak intensities, signal to noise ratio, peak separation and
shape).
Activomics and serum check
The activities obtained with each set of 10 samples were compared to 10 control sera on the
same screening plate and normalised to this activity to enable (Fig 3A) inter-experiment
Fig 2. Chromatogram of 2-AB labeled N-linked glycans released from the plasma proteins and separated by HILIC-UPLC. The small vertical bars
below the 0 level denote the integration area for each peak, and the major chemical structure present in each glycan group (GP1-GP39) is given above
each peak. Data points represent medium of at least the duplicate for each samples with the P-values (-log10) for the analysis of associations
between plasma glycans and LBP diagnosed at the time of blood collection for glycome analysis.
https://doi.org/10.1371/journal.pone.0176372.g002
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comparisons and collective analysis of the samples as a whole group (Fig 3B). This provided
enough samples to perform a Receiver Operator Characteristic (ROC) analysis (N = 50), in
order to characterise marker performance (Fig 4).
In other studies, the Act02 marker has been shown to measure erroneously high levels of
activity in poorly handled samples (presumably arising from uncontrolled cell lysis), allowing
Fig 3. Test of sample integrity. Normalised carboxypeptidase activity for PainOmics samples analysed (A)
by centre and (B) as a whole PainOmics group versus control serum samples. (Control = 1.0 ± 0.1 versus
PainOmics = 1.0 ± 0.2; unpaired t test P = 0.6). Each data point represents an individual patient sample
(average of n = 8 replicates).
https://doi.org/10.1371/journal.pone.0176372.g003
Validation of SOPs
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accurate identification of centres using these different techniques (by ROC analysis
AUC> 0.9). In the current validation study no such variation was seen between centres for
the first 10 samples tested providing a further control for sample preparation, handling and
transport (Fig 5).
Discussion
Chronic Low Back Pain (CLBP) is an unresolved phenomenon sustained by complex physi-
ological changes, which may lead to chronic syndrome with high socioeconomic costs [14].
Identification of ‘-omics’ biomarkers plays a critical role in the development of patient-spe-
cific therapies and individualized medicine, and as such offers great opportunities for
Fig 4. ROC analysis of normalised Act_A11 activity with PainOmics versus control serum samples.
The Area Under the Curve (AUC) of 0.51 ± 0.06 indicates this marker is essentially invariant between serum
controls versus PainOmics samples, thereby confirming the homogeneity of the various samples received.
https://doi.org/10.1371/journal.pone.0176372.g004
Fig 5. Test of sample preparation. The activity of the PainOmics samples was analysed by centre (points
represent the average activity for each patient (n = 4). These data indicate the homogeneity of serum sample
preparation for our analyses. The presence of several outliers from different centres suggest some variation
exists between patient samples for this marker.
https://doi.org/10.1371/journal.pone.0176372.g005
Validation of SOPs
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fighting the current limitations of chronic pain management. The transition from acute to
chronic pain is related to genetic background and post-translational modifications [15, 16],
which could be investigated through genomics [17], glycomics [18] and activomics [19]
approaches.
To establish consistency in our multidisciplinary and international study and the secondary
integration for the correct and common preparation of biological samples among all members
of the consortium, it was necessary to create comprehensive standard operating procedures
(SOPs). This approach had ensured repeatability of the experiments and transferability of the
data.
We have developed and validated personalised SOPs for the handling of biological samples
for the management and traceability of samples from patients enrolled in a multicenter multi-
disciplinary -omics study, in order to guarantee reliable results, independent of the clinical
centre that isolated the sample. Our results, obtained from the first 10 patients enrolled from
each clinical centre, suggest that the three SOPs are suitable for the -omics analyses.
Moreover, strict adherence to these SOPs and centralized data analysis, with clinical data
stored in an annotated database, it resulted in with a better reproducibility obtaining high-
Fig 6. Schematic representation of the validation of personalized SOPs.
https://doi.org/10.1371/journal.pone.0176372.g006
Validation of SOPs
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quality clinical endpoints correlating our genomics, glycomics and activomics data with others
new -omics determinants [20]. Indeedthe study details were already published in our first
manuscript[12] underling how it was important to adopt the technically sound and standard-
ized procedures (an harmonisation of the procedures from collecting, handling, shipping to,
finally, analysing of each samples)to get the best result in a large number of the patient’ samples
managed in all the Centres participating in this study.
Therefore, we think that our personalized SOPs may be useful for the scientific community
to manage large numbers of heterogeneous samples, having same experimental procedures
and meanwhile preserving and improving respectively the individuality of the clinical and
methodological aspects, usable by all without other instructions but with a simple and immedi-
ate consultation of the steps to pursue the reproducibility and accuracy of the results (Fig 6).
Nevertheless, SOPs remain largely exploratory and may require a re-evaluation from the prac-
tical point of view after their implementation in the ongoing worldwide study.
Next step will be to implement even more our SOPs introducing cryotubes with a chip-
readable database connected to an laboratory information management system (LIMS). In this
way we can trace better all the activities performed with this sample, making it traceable and
identifying the most suitable samples for subsequent analysis. All these data could be uploaded
in a web-based database in order both to have a online access to all data and, eventually, to





S2 File. SOP-PAIN-OMICS-0003-Plasma -Blood Sampling-v3.0.
(PDF)
S3 File. SOP-PAIN-OMICS-0002-Serum -Blood Sampling-v2.0.
(PDF)
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